gebhart/patrepeval huggingface dataset:
Mitral reconstruction in cardiomyopathy. (2002)

Functional mitral regurgitation (MR) is a significant complication of end-stage cardiomyopathy, and may affect most heart failure patients as a pre-terminal or terminal event as it develops secondary to a change in the annular-ventricular apparatus and altered ventricular geometry; this results in incomplete leaflet coaptation.. Historically, surgery in MR patients was mitral valve replacement, but the adverse effects on LV systolic function of interrupting annulus-papillary muscle continuity was poorly understood. At the University of Michigan (1993-2000), 140 patients with end-stage cardiomyopathy and refractory MR underwent mitral valve repair with an undersized flexible annuloplasty ring. All were in NYHA class III/IV despite receiving maximal medical therapy, and had severe LV systolic dysfunction (ejection fraction (EF) <25%). Overall operative mortality was 5%. There were five 30-day mortalities (one intraoperative death due to right ventricular failure, one cardiac failure, one stroke, two multisystem organ failure). Five patients required intra-aortic balloon pump IABP support, but no patients required a LV assist device. Mean follow up was 38 months (range: 1-68 months); one- and two-year actuarial survival was 80% and 70%, respectively. There were 26 late deaths. At postoperative echocardiography the mean transmitral gradient was 3 +/- 1 mmHg (range: 2-6 mmHg). At two-year follow up, all patients were in NYHA class I/II, with mean EF 26%. NYHA class was improved in all patients, and all reported subjective improvement in functional status. Improvements were shown in LV EF, cardiac output, and end-diastolic volumes, with reduced sphericity index and regurgitant fraction. Though significant undersizing of the mitral annulus was used to over-correct for the zone of coaptation, no mitral stenosis was induced, nor was any systolic anterior motion (SAM) noted. SAM was avoided due to widening of the aortomitral angle and increased LV size seen in myopathic patients. In conclusion, surgical therapies of heart failure are rapidly expanding and evolving. As a result of improvements in preoperative selection, intraoperative techniques and postoperative care, high mortality and morbidity after surgical intervention in patients with end-stage heart disease no longer apply. By combining operative techniques with optimal medical management of heart failure, good outcome can avoid or postpone transplantation. This strategy will help to preserve the limited number of donor organs for those patients with no other surgical or medical alternatives.
Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide (2015)

Related HLA-haploidentical blood or marrow transplantation (BMT) with high-dose posttransplantation cyclophosphamide (PTCy) is being increasingly used because of its acceptable safety profile. To better define outcomes of nonmyeloablative (NMA) HLA-haploidentical BMT with PTCy, 372 consecutive adult hematologic malignancy patients who underwent this procedure were retrospectively studied. Risk-stratified outcomes were evaluated using the refined Disease Risk Index (DRI), developed to stratify disease risk across histologies and allogeneic BMT regimens. Patients received uniform conditioning, T-cell-replete allografting, then PTCy, mycophenolate mofetil, and tacrolimus. Six-month probabilities of nonrelapse mortality and severe acute graft-versus-host disease were 8% and 4%. With 4.1-year median follow-up, 3-year probabilities of relapse, progression-free survival (PFS), and overall survival (OS) were 46%, 40%, and 50%, respectively. By refined DRI group, low (n = 71), intermediate (n = 241), and high/very high (n = 60) risk groups had 3-year PFS estimates of 65%, 37%, and 22% (P < .0001), with corresponding 3-year OS estimates of 71%, 48%, and 35% (P = .0001). On multivariable analyses, the DRI was statistically significantly associated with relapse, PFS, and OS (each P < .001). This analysis demonstrates that the DRI effectively risk stratifies recipients of NMA HLA-haploidentical BMT with PTCy and also suggests that this transplantation platform yields similar survivals to those seen with HLA-matched BMT.
Clinical Potential of Magnetic Resonance Spectroscopy in Renal Disease (1985)

Magnetic resonance spectroscopy (MRS), especially of 31 phosphorus, seeks to collect biochemical and metabolic information related to energy metabolism, intracellular pH, and oxygen delivery to the kidney (1,2). Earlier applications in clinical medicine have been established in diagnosis of metabolic myopathy (3,4), infantile cerebral anoxia (5), stroke (6,7), and in vascular insufficiency of the lower limb (8).
A Cell-Permeable Inhibitor to Trap Gαq Proteins in the Empty Pocket Conformation (2020)

In spite of the crucial role of heterotrimeric G proteins as molecular switches transmitting signals from G protein-coupled receptors, their selective manipulation with small molecule, cell-permeable inhibitors still remains an unmet challenge. Here, we report that the small molecule BIM-46187, previously classified as pan-G protein inhibitor, preferentially silences Gαq signaling in a cellular context-dependent manner. Investigations into its mode of action reveal that BIM traps Gαq in the empty pocket conformation by permitting GDP exit but interdicting GTP entry, a molecular mechanism not yet assigned to any other small molecule Gα inhibitor to date. Our data show that Gα proteins may be “frozen” pharmacologically in an intermediate conformation along their activation pathway and propose a pharmacological strategy to specifically silence Gα subclasses with cell-permeable inhibitors.
Minimal residual disease in peripheral blood at day 15 identifies a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with superior prognosis (2011)

Minimal residual disease in peripheral blood at day 15 identified a large group of patients with an excellent prognosis and added prognostic information to the risk stratification based on minimal residual disease at day 33 and week 12.
Enabling Wide Autonomous DVFS in a 22 nm Graphics Execution Core Using a Digitally Controlled Fully Integrated Voltage Regulator (2015)

A digitally-controlled fully integrated voltage regulator (IVR) enables wide autonomous DVFS in a 22 nm graphics execution core. Part of the original power header is converted into a hybrid power stage to support digital low-dropout (DLDO), and switched-capacitor voltage regulator (SCVR) modes, in addition to the original bypass and sleep modes. Using voltage sensing, tunable replica circuit, or a core warning signal, the IVR detects and quickly responds to fast voltage droops to support fast dynamic workload changes without performance degradation. In a prototype, a 3D graphics execution core is powered up by the proposed hybrid IVR demonstrating measured 26% and 82% reduction in core energy in the turbo and the near-threshold voltage (NTV) modes, respectively. The total area overhead of the proposed hybrid IVR is 4% of the core compared to 2% from the original power header. Our digitally assisted control for the droop response shows ~ 75% core frequency improvement at 0.84 V.
P1134: OUTCOMES FOR PATIENTS WITH MANTLE CELL LYMPHOMA POST-CBTK INHIBITOR THERAPY IN THE UNITED STATES AND JAPAN: A STUDY OF TWO REAL-WORLD DATABASES (2022)

Background: Patients with mantle cell lymphoma (MCL) have limited treatment options following covalent Bruton’s tyrosine kinase inhibitor (cBTKi) therapy, with no standard regimens defined. Aims: The aim of this study was to investigate real-world treatment patterns and the outcomes for patients with MCL following cBTKi treatment utilizing two separate datasets—one from the US and one from Japan. Methods: De-identified patient-level electronic medical record data from two real-world databases (ConcertAI in the US and Medical Data Vision in Japan) were utilized for this study. Eligible patients were ≥18 years old and were diagnosed with MCL between January 2011 and October 2020 in the US or between December 2010 and July 2020 in Japan. Data were available through 2020 to allow a minimum of 1 year of follow-up for all patients. Patients were required to have completed treatment with at least one cBTKi during the first through third lines of therapy. Time-to-event analyses utilized the Kaplan-Meier method. Results: 946 US patients (median age 72 years, male 75.1%) and 196 Japanese patients (median age 78 years, male 73.5%) met the eligibility criteria. 352 (37.2%) patients in the US and 103 (52.6%) in Japan received subsequent post-cBTKi therapy. The remaining 387 (40.9%) patients in the US and 93 (47.5%) patients in Japan did not receive further treatment. In the US, immediate post-cBTKi regimens included rituximab (with or without other chemotherapy agents, n=152, 43.2%) or additional cBTKi-based 146 (41.5%) or B-cell lymphoma 2 inhibitor–based (n=30, 8.5%) therapy. In Japan, immediate post-cBTKi regimens were nearly exclusively chemotherapy based (n=92, 89.3%), and only 11 (10.7%) patients were retreated with cBTKi-containing regimens. Median time from the end of cBTKi therapy to discontinuation of the immediate post-cBTKi therapy or death was 3.9 months (95% confidence interval [CI]: 3.3-4.6) in the US and 2.4 months (n=196, 95% CI: 1.7-3.0) in Japan. Among those who received post-cBTKi therapy, the duration of therapy was 2.6 months (95% CI: 2.1-3.3) in the US and 1.8 months (n=103, 95% CI: 1.1-2.3) in Japan. Median overall survival (OS) from discontinuation of cBTKi therapy was 10.3 months (95% CI: 8.0-13.0 in US patients and 7.1 months (n=196, 95% CI: 4.6-12.7) in Japanese patients. Summary/Conclusion: Patients with MCL previously treated with cBTKi experience very poor outcomes, as measured by their duration of subsequent therapy and OS. Data were generally consistent between the US and Japan. The development of new safe and effective therapies after cBTKi is needed to address the growing unmet medical need in this treatment setting.
Integrins: dynamic regulation of ligand binding (1995)

Conference Article| August 01 1995 Integrins: dynamic regulation of ligand binding M. H. Ginsberg M. H. Ginsberg 1Department of Vascular Biology, The Scripps Research Institute, 10666 N. Torrey Pines, La Jolla, CA 92037, U.S.A. Search for other works by this author on: This Site PubMed Google Scholar Biochem Soc Trans (1995) 23 (3): 439–446. https://doi.org/10.1042/bst0230439 Article history Received: March 09 1995 Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn MailTo Cite Icon Cite Get Permissions Citation M. H. Ginsberg; Integrins: dynamic regulation of ligand binding. Biochem Soc Trans 1 August 1995; 23 (3): 439–446. doi: https://doi.org/10.1042/bst0230439 Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest filter your search All ContentAll JournalsBiochemical Society Transactions Search Advanced Search Keywords: PKC, protein kinase C This content is only available as a PDF. © 1995 Biochemical Society1995 Article PDF first page preview Close Modal You do not currently have access to this content.
Industrial Waste Combustion Boiler Installed at Paper Mill (2003)

From the problem of global warming, the reduction of CO2 emission is large proposition, and Paper manufactures have utilized positively biomass and industrial waste from a viewpoint of environmental protection. EBARA Internally Circulating Fluidized Bed Boiler (ICFB) co-combusts efficiently many kinds of fuel, is suitable for industrial waste and biomass combustion boiler. Internally Circulating Fluidized Bed Gasifier (ICFG) is new technology and featured making it possible for a recovery of clean gaswithout combustion gas.
1116: Improved Stone Comminution and Simultaneously Reduced Tissue Injury with an Upgraded Electrohydraulic Lithotripter: in Vivo Studies (2004)

You have accessJournal of UrologyDiscussed Poster, Monday, May 10, 2004, 1:00 - 5:00 pm1 Apr 20041116: Improved Stone Comminution and Simultaneously Reduced Tissue Injury with an Upgraded Electrohydraulic Lithotripter: in Vivo Studies Charles G. Marguet, Matthew D. Young, Michaella E. Malloney, Wesley Ekeruo, W. Patrick Springhart, James O. L'Esperance, Yeh Hong Tan, David M. Albala, Yufeng Zou, Pei Zhong, and Glenn M. Preminger Charles G. MarguetCharles G. Marguet More articles by this author , Matthew D. YoungMatthew D. Young More articles by this author , Michaella E. MalloneyMichaella E. Malloney More articles by this author , Wesley EkeruoWesley Ekeruo More articles by this author , W. Patrick SpringhartW. Patrick Springhart More articles by this author , James O. L'EsperanceJames O. L'Esperance More articles by this author , Yeh Hong TanYeh Hong Tan More articles by this author , David M. AlbalaDavid M. Albala More articles by this author , Yufeng ZouYufeng Zou More articles by this author , Pei ZhongPei Zhong More articles by this author , and Glenn M. PremingerGlenn M. Preminger More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(18)38353-8AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail "1116: Improved Stone Comminution and Simultaneously Reduced Tissue Injury with an Upgraded Electrohydraulic Lithotripter: in Vivo Studies." The Journal of Urology, 171(4S), p. 294 © 2016 by American Urological AssociationFiguresReferencesRelatedDetails Volume 171Issue 4SApril 2004Page: 294 Advertisement Copyright & Permissions© 2016 by American Urological AssociationMetricsAuthor Information Charles G. Marguet More articles by this author Matthew D. Young More articles by this author Michaella E. Malloney More articles by this author Wesley Ekeruo More articles by this author W. Patrick Springhart More articles by this author James O. L'Esperance More articles by this author Yeh Hong Tan More articles by this author David M. Albala More articles by this author Yufeng Zou More articles by this author Pei Zhong More articles by this author Glenn M. Preminger More articles by this author Expand All Advertisement PDF DownloadLoading ...
Synthesis and preliminary PET study of the 5‐HT7 receptor antagonist [11C]DR4446 (2002)

Abstract DR4446 (1‐methyl‐2a‐[4‐(4,5,6,7‐tetrahydrothieno[3,2‐ c ]pyridin‐5‐yl)butyl]‐2 a ,3,4,5‐tetrahydro‐1H‐benz[ cd ]indole‐2‐one) is a potent 5‐HT 7 receptor antagonist ( K i =9.7 nM) with a high selectivity over other 5‐HT family receptors ( K i for 5‐HT 1A : 770 nM; for other 5‐HT receptors: &gt;1000 nM). As a positron emission tomography (PET) tracer for the 5‐HT 7 receptor, [ 11 C]DR4446 was synthesized at high radiochemical purity ( &gt;98%) with specific activity of 73–120 GBq/μmol at the end of synthesis by the alkylation of the desmethyl precursor (1) with [ 11 C]CH 3 I in the presence of NaH. A PET study in monkey demonstrated that [ 11 C]DR4446 had good permeability into the brain, and had a specific binding component in the brain regions including the thalamus, possibly an area in the 5‐HT 7 receptors. Metabolite analysis showed that [ 11 C]DR4446 was relatively stable and low percentages of two radio‐labeled metabolites were detected in the plasma of monkey using HPLC. Copyright © 2002 John Wiley &amp; Sons, Ltd.
Standardization Transparency - An Out of Body Experience. (2014)

This paper examines the issue of transparency in standards setting organization processes used to select security techniques for standardization. Analysis of data collected from interviews, electronic mail, and other documen- tation is presented as a narrative in two case studies. A Kaleidoscope confer- ence case study illustrates the positive impacts of open participation on improv- ing transparency through the reduction of bias in the selection process. These impacts include more timely inputs from researchers on emerging technology issues, and greater diversity in the sources of creative new ideas and solutions considered for standardization. Restrictions imposed on the selection process by government control of national body activities are described through a second case study of practice in the United States. Finally, recommendations are pro- posed on actions standards setting organizations can take to broaden participa- tion in the selection of techniques for standardization and to strengthen commu- nications between standards developers and the research community.
Bilattice-based Logical Reasoning for Human Detection (2007)

The capacity to robustly detect humans in video is a critical component of automated visual surveillance systems. This paper describes a bilattice based logical reasoning approach that exploits contextual information and knowledge about interactions between humans, and augments it with the output of different low level detectors for human detection. Detections from low level parts-based detectors are treated as logical facts and used to reason explicitly about the presence or absence of humans in the scene. Positive and negative information from different sources, as well as uncertainties from detections and logical rules, are integrated within the bilattice framework. This approach also generates proofs or justifications for each hypothesis it proposes. These justifications (or lack thereof) are further employed by the system to explain and validate, or reject potential hypotheses. This allows the system to explicitly reason about complex interactions between humans and handle occlusions. These proofs are also available to the end user as an explanation of why the system thinks a particular hypothesis is actually a human. We employ a boosted cascade of gradient histograms based detector to detect individual body parts. We have applied this framework to analyze the presence of humans in static images from different datasets.
Mapping Moisture Sorption Through Carbohydrate Composite Glass with Fourier Transform Near-Infrared (FT-NIR) Hyperspectral Imaging (2014)

Inherent changes in foods during storage are often caused by water sorption or desorption that often results in product matrix instability. Water sorption behavior differs depending on the matrix through which it moves. Often, concurrent phenomenon such as crystallization modifies water's movement. We describe a novel use of hyperspectral imaging combined with Fourier Transform Near Infrared (FT-NIR) spectroscopy to map where water molecules are in two dimensions while concurrently quantifying the crystallization motif as water sorbs into a carbohydrate matrix over a month's storage time. This methodology allows us to identify and quantify sucrose crystals formed within a carbohydrate matrix while also mapping water migration through this complex matrix. We compared corn syrup/sucrose blends where sucrose is supersaturated (high sucrose, HS), sucrose is below saturation (low sucrose, LS), sucrose below saturation with embedded sucrose crystals (LSS) and maltotriose is supersaturated within a corn syrup matrix (high maltotriose, LSM). This FT-NIR method was used to characterize water sorption through a carbohydrate matrix over time and measured both the propensity of the systems to form sucrose crystals and the influence sucrose crystals have on water sorption. We observed water diffusion was slower in lower sugar carbohydrate glasses, and the process of sorption was different. Amorphous systems supersaturated in sucrose allow crystallization when sufficient water is sorbed and thus, this concurrent action disrupts normal Fickian diffusion. The water front compresses to a narrow band as it sorbs through the matrix. The presence of embedded crystals in an amorphous matrix slows overall water penetration through the matrix by convoluting the path of moving water molecules. This did not appear to change the rate of diffusion. Experiments with maltotriose at supersaturation concentration showed the crystallization rate was slower than sucrose. Thus, pure maltotriose is not a practical solution as a potential replacement for sucrose to slow sorption in food systems.
A two-time-scale neural tracking controller for a class of nonlinear dynamical systems (2005)

A two-time-scale neural controller with application to tracking control for a class of nonlinear dynamical systems is introduced, and its stability is analyzed. The feasibility of the proposed controller is demonstrated by simulation of a two-link rigid robot arm.< <ETX xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&gt;</ETX>
Enhancing photodynamic therapy of a metastatic mouse breast cancer by immune stimulation (2006)

One in 8 women in the United States will develop breast cancer during her lifetime and 40,000 die each year. Deaths are due to tumors that have metastasized despite local control. Photodynamic therapy (PDT) is a promising cancer treatment in which a photosensitizer (PS) accumulates in tumors and is subsequently activated by visible light of an appropriate wavelength. The energy of the light is transferred to molecular oxygen to produce reactive oxygen species that produce cell death and tumor ablation. Mechanisms include cytotoxicity to tumor cells, shutting down of the tumor vasculature, and the induction of a host immune response. The precise mechanisms involved in the PDT-mediated induction of anti-tumor immunity are not yet understood. Potential contributing factors are alterations in the tumor microenvironment via stimulation of proinflammatory cytokines and direct effects of PDT on the tumor that increase immunogenicity. We have studied PDT of 410.4 variant 4T1 tumors growing in the mammary fat pad (orthotopic) in Balb/c mice and which produce metastasis. We have shown that a PDT regimen that produces vascular shutdown and tumor necrosis leads to initial tumor ablation but the tumors recur at the periphery. We studied the combination of PDT with immunostimulating therapies. Low dose cyclophosphamide (CY) is a specific mechanism to deplete the regulatory T cells (CD4+CD25+), these cells play an important role in the immunosuppression activity of tumors. In combination with PDT that produces release of tumor specific antigens, this immunostimulation may lead to generation of cytotoxic CD8 T-lymphocytes that recognize and destroy the tumor. The second alternative therapy is the use of a novel combination of the immunostimulant CpG oligodeoxynucleotides (CpG-ODN) and PDT. CpG-ODN is recognized by Toll-like receptor 9 and directly or indirectly triggers B cells, NK cells, monocyte-macrophages and dendritic cells to proliferate, mature and secrete cytokines, chemokines and immunoglobulins. Both these novel combinations gave significantly enhanced therapeutic benefit not seen with single treatments alone. Tumors grew more slowly and mice lived significantly longer, although cures were rare. We propose that a rational choice of immune stimulant is an ideal addition to PDT regimens.